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OBJECTIVE — To examine the effects of acute insulin-induced hypoglycemia on inﬂamma-
tion, endothelial dysfunction, and platelet activation in adults with and without type 1 diabetes.
RESEARCH DESIGN AND METHODS — We studied 16 nondiabetic adults and 16
subjects with type 1 diabetes during euglycemia (blood glucose 4.5 mmol/l) and hypoglycemia
(blood glucose 2.5 mmol/l). Markers of inﬂammation, thrombosis, and endothelial dysfunction
(soluble P-selectin, interleukin-6, von Willebrand factor [vWF], tissue plasminogen activator
[tPA], high-sensitivity C-reactive protein [hsCRP], and soluble CD40 ligand [sCD40L]) were
measured; platelet-monocyte aggregation and CD40 expression on monocytes were determined
using ﬂow cytometry.
RESULTS — In nondiabetic participants, platelet activation occurred after hypoglycemia,
with increments in platelet-monocyte aggregation and P-selectin (P  0.02). Inﬂammation was
triggered with CD40 expression increasing maximally at 24 h (3.13  2.3% vs. 2.06  1.0%)
after hypoglycemia (P  0.009). Both sCD40L and hsCRP (P  0.02) increased with a nonsig-
niﬁcant rise in vWF and tPA, indicating a possible endothelial effect. A reduction in sCD40L,
tPA, and P-selectin occurred during euglycemia (P  0.03, P  0.006, and P  0.006, respec-
tively).Intype1diabetes,bothCD40expression(5.544.4%vs.3.651.8%;P0.006)and
plasma sCD40L concentrations increased during hypoglycemia (peak 3.41 3.2 vs. 2.85 2.8
ng/ml; P  0.03). Platelet-monocyte aggregation also increased signiﬁcantly at 24 h after hypo-
glycemia (P  0.03). A decline in vWF and P-selectin occurred during euglycemia (P  0.04).
CONCLUSIONS — Acute hypoglycemia may provoke upregulation and release of vasoac-
tivesubstancesinadultswithandwithouttype1diabetes.Thismaybeaputativemechanismfor
hypoglycemia-induced vascular injury.
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I
n people with type 1 diabetes the rapid
institution of strict glycemic control
aggravates microvascular complica-
tions, particularly retinopathy (1). Al-
though attributed to reduced capillary
bloodﬂowcausinglocalizedischemia(1),
greater exposure to hypoglycemia may
have worsened microangiopathy through
its putative effects on local vasculature
(2). In addition, cardiovascular stress as-
sociated with hypoglycemia may precipi-
tate acute macrovascular events in a
diseased circulation. While supported by
anecdotal reports (3), the increase in car-
diovascular mortality in people with type
2 diabetes in the Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
trial (4) (and possibly in the Veterans Af-
fairs Diabetes Trial [5]), in which inten-
sive treatment had tripled the frequency
of severe hypoglycemia, has caused
concern.
Possible mechanisms by which hypo-
glycemia may damage blood vessels in-
clude changes in regional blood ﬂow,
mobilization and activation of neutro-
phils, platelet activation, and enhanced
coagulation and viscosity of the blood
(3,6–8). Plasma concentrations of C-
reactive protein, interleukin-6 (IL-6),
and endothelin-1 increase during hypo-
glycemia (9–11) and may promote vas-
cular disease (12).
Investigation of processes operating
at a cellular level to cause atherosclerosis
has focused on the potential inﬂuences
of vascular inﬂammation, endothelial
dysfunction, coagulation, and platelet ac-
tivation. The present study sought to de-
termine the effects of acute insulin-
induced hypoglycemia on inﬂammation,
coagulation, and platelet and monocyte
functioninadultswithandwithouttype1
diabetes.
RESEARCH DESIGN AND
METHODS— Participants in the
study included 16 nondiabetic adult vol-
unteers with no medical history and 16
healthy adults with type 1 diabetes (Table
1). Those with diabetes had no history of
hypertension or macrovascular disease,
and microvascular disease was excluded.
Screeningforretinopathyuseddigitalret-
inal photography, absence of neuropathy
was conﬁrmed by clinical examination,
andnephropathywasexcludedbytheab-
sence of microalbuminuria. Subjects with
a history of impaired awareness of hypo-
glycemia or a previous serious reaction to
hypoglycemiawereexcluded.Nonehada
history of head injury, seizure, blackouts,
alcohol or drug abuse and psychiatric ill-
ness, and their only other medication was
the contraceptive pill. Diabetes Control
and Complications Trial–aligned A1C
was measured using high performance
liquid chromatography (nondiabetic ref-
erence range 5.0–6.05%; Bio-Rad Labo-
ratories, Munich, Germany); the mean 
SD of the participants with diabetes was
7.91  0.92%. All gave written informed
consent before participation, and the
study was approved by the Local Medical
Research Ethics Committee.
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clamp (13) was used to maintain blood
glucoseatapredeterminedlevel:euglyce-
mia at 4.5 mmol/l and hypoglycemia at
2.5 mmol/l. Each subject underwent two
laboratorysessions,separatedbyatleast2
weeks (mean 7.2 weeks), of a euglycemic
study and a hypoglycemic study in a ran-
domized, counterbalanced fashion.
The participants with type 1 diabetes
monitored blood glucose intensively dur-
ing the 48 h preceding each study, which
was postponed if any blood glucose value
was 3.5 mmol/l or if symptoms sugges-
tive of hypoglycemia were experienced.
After fasting overnight, morning insulin
was withheld. A retrograde-intravenous
cannula for blood-glucose sampling was
inserted into the nondominant hand,
whichwasheatedtoarterializethevenous
blood (14). A cannula in the nondomi-
nant antecubital fossa was used to infuse
20% dextrose and soluble insulin (Hu-
man Actrapid; Novo Nordisk, Crawley,
U.K.) at a constant rate of 1.5 mU/kg/min
using a Gemini PCI pump (Alaris Medical
Systems, San Diego, CA). The dextrose
was infused at a variable rate depending
on arterialized blood glucose concentra-
tions, which were measured at 5 min in-
tervals using the glucose oxidase method
(2300 Stat; Yellow Springs Instruments,
Yellow Springs, OH). A third cannula in
the other antecubital fossa was dedicated
to blood sampling for inﬂammatory
markers.
On each study day, the arterialized
blood glucose was stabilized initially at
4.5 mmol/l for 30 min and either main-
tained at that level (euglycemia) or low-
eredover20minto2.5mmol/lfor60min
(hypoglycemia), after which blood glu-
cose was restored to 4.5 mmol/l. Subjects
consumed a standardized meal after each
study. Blood sample time points were:
baseline, during the experimental session
(45 min), during recovery (105 min),
at 6 h, and at 24 h.
Flow cytometry
Whole blood samples were collected
at the predetermined time points using
D-Phenylalanyl-L-prolyl-L-arginine chlo-
romethyl ketone, a selective thrombin in-
hibitor,asananticoagulant.Samples(100
l) of whole blood were immediately in-
cubated with 10 l of each monoclonal
antibody (AbD Serotec, Kidlington, U.K.)
for 30 min at room temperature, with
subsequent red cell lysis by the addition
of 1 ml of ﬂuorescent-activated cell sorter
(FACS) Lyse solution (Becton Dickinson,
Oxford, U.K.). Flow cytometry using the
FACS Calibur system (Becton Dickinson,
Oxford, U.K.) was performed immedi-
ately after the experimental session to as-
sess platelet-monocyte aggregation
(CD14/CD42a) and CD40 expression on
monocytes (CD14/CD40). Isotype con-
trols were performed in addition to both
mono- and dual-stain for each parameter
assessed at each time point.
Soluble marker assays
Citrated plasma and serum samples
were collected at the predetermined
time points. These were separated imme-
diatelyandfrozenat80°Cuntilanalysis
for the soluble markers:
VonWillebrandfactor(vWF)(enzyme-
linkedimmunosorbentassay[ELISA];co-
efﬁcient of variation [CV] 7.3%), tissue
plasminogen activator (tPA) antigen (Hy-
phen Biomed Zymutest; intra-assay CV
3.5%, inter-assay CV 4.4%), soluble
CD40 ligand (sCD40L) (high sensitivity
ELISA, Bender Medsystems; intra-assay
CV 5.5%, inter-assay CV 7.2%), soluble
P-selectin (ELISA, R&D Systems; intra-
assay CV 5.1%, inter-assay CV 8.8%),
IL-6 (High sensitivity ELISA, R&D Sys-
tems;intra-assayCV5.9%,inter-assayCV
9.9%),andhighsensitivityCRP(DRGDi-
agnostics; DRG Instruments, Marburg,
Germany; intra-assay CV 4.2%, inter-
assay CV 4.1%).
Catecholamine assays
Samples for epinephrine quantiﬁcation
were collected in EDTA tubes and imme-
diately separated and frozen at 80°C
until analysis by high-performance liquid
chromatography and electrochemical de-
tection (intra-assay CV 1.2%, inter-assay
CV 3.9%).
Hypoglycemia symptom score
The Edinburgh Hypoglycemia Scale (15)
was used to assess the symptoms experi-
enced during each experimental session.
Statistical analyses
Results were analyzed using SPSS version
15.0 for Windows (SPSS, Chicago, IL). A
general linear model (repeated-measures
ANOVA) was used, with order of session
(euglycemia-hypoglycemia or hypoglyce-
mia-euglycemia) as a between-subjects
factor, and condition (euglycemia or hy-
poglycemia)asawithin-subjectsfactor,to
compare hypoglycemia with euglycemia.
Additional analysis using paired t tests
wasperformedtoassessthechangeinany
given parameter from baseline. A P value
0.05 was considered to be signiﬁcant.
Results are reported as mean  SD unless
otherwise stated.
RESULTS— Hypoglycemia provoked
a symptomatic response in all subjects
with increased scores of autonomic (P 
0.002), neuroglycopenic (P  0.001),
and malaise (P  0.008) symptoms com-
pared with baseline. Comparison of base-
line levels of inﬂammatory, endothelial
and platelet markers in nondiabetic sub-
jects and subjects with type 1 diabetes
showed a signiﬁcantly higher concentra-
tion of soluble P-selectin (P  0.01) and
of CD40 expression on monocytes (P 
0.006) in those with diabetes, demon-
strating the chronic inﬂammatory re-
sponse associated with diabetes.
Blood glucose
Targetbloodglucoseconcentrationswere
achieved(Fig.1).Innondiabeticsubjects,
blood glucose concentrations were
2.580.2and4.420.5mmol/lduring
hypoglycemia and euglycemia, respec-
tively. In those with type 1 diabetes, blood
glucose concentrations were 2.46  0.22
and 4.53  0.24 mmol/l, respectively.
The blood glucose nadir was similar in
both groups.
Counterregulatory response
Plasma epinephrine increased during hy-
poglycemiainparticipantswithandwith-
Table 1—Baseline demographic characteristics
Nondiabetic subjects Subjects with diabetes
n 16 16
Age (years) 28 (26.7–35) 28 (25–37.5)
BMI (kg/m
2) 22.86  2.4 26.40  4.0
Male/female 6/10 7/9
Duration of diabetes (years) N/A 10 (4.2–19)
A1C (%) N/A 7.91  0.9
Data are median (interquartile range) and means  SD unless otherwise indicated.
Hypoglycemia and vascular disease
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The epinephrine response occurred only
during hypoglycemia and returned rap-
idly to baseline as anticipated (16).
Platelet activation
Platelet-monocyte aggregation. In non-
diabetic subjects, platelet-monocyte ag-
gregationappearedtorise,fromabaseline
level of 0.72  0.8% to 3.09  8.1%
during hypoglycemia, with a peak of
3.49  10.4% at 24 h (Fig. 2). Platelet-
monocyte aggregation remained un-
changed throughout euglycemia. The
difference between conditions, and
frombaseline,didnotachievestatistical
signiﬁcance.
In participants with diabetes, there
was a late rise in platelet-monocyte aggre-
gation after hypoglycemia at 24 h com-
pared with baseline (P  0.03).
Soluble P-selectin. Soluble plasma P-
selectin concentrations increased after
hypoglycemia in nondiabetic subjects,
exhibiting a late response at6h( P 
0.01) and 24 h (P  0.02; Fig. 2) but
decreasing during euglycemia (P 
0.006).
P-selectin also decreased during eu-
glycemiainthediabeticgroup(P0.04),
but did not change during hypoglycemia.
Endothelial markers
tPA. In nondiabetic subjects, plasma tPA
concentrationsincreasedduringhypogly-
cemia, with a higher peak tPA concentra-
tion (12.55  16.7 compared with
6.80  7.9 ng/ml) (NS between condi-
tions). Plasma tPA decreased signiﬁcantly
between baseline and test phase (P 
0.004) and recovery phase (P  0.006),
with a paradoxical rise between baseline
and24h(P0.06)aftereuglycemia(Ta-
ble2).However,adiurnalvariationintPA
concentration is recognized to occur,
which may account for the decline ob-
servedduringeuglycemia(17).Nosignif-
icant differences occurred in the diabetic
group (Table 2).
vWF. A trend toward a difference in
plasmavWFconcentrationswasobserved
between hypoglycemia and euglycemia at
6hinthenondiabeticsubjects(P0.07)
(Table 2).
Plasma vWF concentrations de-
creased between baseline and test phase
(P0.02)andrecoveryphase(P0.03)
after euglycemia in the participants with
diabetes. No such decrement was ob-
served during hypoglycemia (Table 2).
Inﬂammation
CD40 expression. CD40 expression on
monocytes increased after hypoglycemia
innondiabeticsubjects,fromabaselineof
1.92  2.2% to a maximum of 3.13 
2.3% at 24 h (P  0.009). A signiﬁcant
differencebetweenhypoglycemiaandeu-
glycemia conditions was present at 6 h
(P  0.05) and at 24 h (P  0.04)
(Table 2).
In participants with type 1 diabetes,
monocyte CD40 expression increased
from3.693.4%to5.544.4%during
hypoglycemia (P  0.006), compared
with no change during euglycemia
(3.64  2.0% to 3.65  1.8%, respec-
tively; P  NS). The increment during
Figure 1—A: Blood glucose concentrations during hyperinsulinemic hypoglycemic and euglycemic clamp studies. B: Epinephrine responses to
experimental procedures. i. nondiabetic subjects; ii. subjects with type 1 diabetes.
Wright and Associates
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of the recovery phase and remained un-
changed thereafter (Table 2).
sCD40L. In nondiabetic subjects,
plasma sCD40L concentrations were
higher during hypoglycemia than during
euglycemia (2.80  3.2 vs. 2.41  2.8
ng/ml), with a trend toward signiﬁcance
(P  0.09). A signiﬁcant reduction in
sCD40L concentration occurred during
euglycemia between baseline and recov-
ery phase (P  0.03) (Table 2).
In those with diabetes, a signiﬁcant
difference was observed between the
baseline levels on each study day: 3.36 
2.9 ng/ml on the hypoglycemia day com-
pared with 2.86  2.8 ng/ml on euglyce-
miaday(P0.03),renderingsubsequent
measurementsdifﬁculttocompare.Asig-
niﬁcantdifferencewasagainobservedbe-
tween the experimental condition levels,
with a level of 3.41  3.2 ng/ml during
hypoglycemia and 2.85  2.8 ng/ml dur-
ing euglycemia (P  0.03) (Table 2).
Changes from baseline did not achieve
signiﬁcance.
IL-6. IL-6 levels rose in all experi-
ments, maximally at 6 h, irrespective of
condition, with no clear differences iden-
tiﬁable in either group between the study
conditions (Table 2).
hsCRP. Test phase hsCRP was higher
in all subjects during hypoglycemia
(1.81  1.9 vs. 1.22  1.9 ng/ml in non-
diabetic participants [P  0.02]; 2.72 
3.1 vs. 2.20  2.9 ng/ml in subjects with
diabetes [P  ns]) (Table 2). A signiﬁcant
difference was observed in the baseline
concentrations in the nondiabetic partic-
ipants (P  0.01), frustrating interpreta-
tion of subsequent responses.
CONCLUSIONS— Previous studies
have demonstrated that hypercoagulabil-
ity, platelet and neutrophil activation, C-
reactive protein, IL-6, and Endothelin-1
are upregulated after acute hypoglycemia
(3,6–11), while a euglycemic insulin in-
fusion (for at least 2 h) was shown to re-
duce inﬂammatory markers, consistent
with an anti-inﬂammatory effect of insu-
lin (18). The present study sought to
replicate these effects, while investigat-
ing other underlying mechanisms of
vascular disease, and tests were selected
to investigate the effect of acute hypo-
glycemia on important cellular pro-
cesses (platelet activation, endothelial
dysfunction and inﬂammation) under-
lying the development of acute and
chronic vascular complications in type
1 diabetes.
The present study showed that hypo-
glycemia generated a response in some of
thesemarkers,suggestingthathypoglyce-
mia-induced metabolic stress may have
adversepathophysiologicalconsequences
while the euglycemic insulin infusion
caused a potentially beneﬁcial decrement
insomeparameters.However,themagni-
tude of most observed changes was small,
andnotallmarkerschangedsigniﬁcantly.
The present study conﬁrmed that
platelet activation is promoted by hypo-
glycemia (8), with increments both in
platelet-monocyte aggregation and solu-
ble P-selectin. Conversely, P-selectin de-
creased during euglycemia. Endothelial
function, using vWF and tPA Ag as surro-
gate markers, may have been disrupted,
as shown by the increase in vWF after
hypoglycemia in nondiabetic volunteers,
but this change was not replicated in
those with diabetes. However, a reduc-
Figure 2—Platelet activation in response to experimental hypoglycemia and euglycemia. A: Platelet-monocyte aggregation. B: Soluble P-selectin,
i. Nondiabetic subjects, ii. Subjects with type 1 diabetes.
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diabetic participants, which should con-
fer vascular beneﬁt. tPA Ag also appeared
toincreaseinnondiabeticsubjectsduring
hypoglycemia,whiledecliningduringeu-
glycemia, whereas no signiﬁcant changes
occurred in the diabetic group. Soluble
markers of inﬂammation, sCD40L and
hsCRP, were higher during hypoglyce-
mia,withanelevationofhsCRPbeingob-
served in all subjects. Unfortunately,
baseline differences in hsCRP in nondia-
betic subjects, and in sCD40L in the dia-
betic subjects, frustrated interpretation of
subsequent responses. sCD40L was ap-
parently reduced during euglycemia in
nondiabetic participants. Surprisingly,
IL-6 increased in all experiments regard-
less of glycemic status, with a maximal
response at 6 h. This response is inexpli-
cable, and contrasts with a previous re-
port (10). Monocyte CD40 expression
also increased, suggesting promotion of
the interaction of the CD40-CD40 ligand
dyad (from the tumor necrosis factor re-
ceptor family), thus affecting another
process in the pathway leading to athero-
sclerotic plaque rupture (19,20). This
change occurred much earlier in the dia-
betic than the nondiabetic subjects, in
whom the response was delayed, pro-
longed, and still present at 24 h. The per-
sistenceofthesevascularchangesfor24h
after the hypoglycemic stimulus, or their
later emergence, suggests that the period
of risk after hypoglycemia may be present
long after blood glucose recovery.
For some markers, a positive trend
after hypoglycemia was evident, without
achieving statistical signiﬁcance, or the
only measurable difference between con-
ditions was a beneﬁcial effect associated
with euglycemia. The sample size may
have been insufﬁcient to achieve signiﬁ-
cance,particularlyasthemagnitudeofre-
sponses was small. It was not feasible to
study a larger number of subjects using a
procedure that is labor-intensive and
costly. In a previous study, larger incre-
ments in inﬂammatory markers were ob-
served during an insulin tolerance test,
wherehypoglycemiaof39mg/dl(2.2
mmol/l) was induced (21). The more
rapid reduction to a lower blood glucose
causing a greater hypoglycemic stimulus
may have heightened the magnitude of
the responses, compared with the more
modest changes that occurred during a
controlled glucose clamp (blood glucose
2.5 mmol/l [45 mg/dl]), as observed in
the present study. A further limitation
of the present study was the need to ex-
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separate days in a counterbalanced fash-
ion. Because the baseline levels of many
inﬂammatory markers can differ on sepa-
rate days, as was observed with sCD40L
and hsCRP, this biological variability hin-
derstheinterpretationandcomparisonof
subsequent results. However, the present
study design was necessary to allow com-
parisonoftheeuglycemiaandhypoglyce-
mia conditions in individual subjects, as
both time and insulin infusion per se may
exert effects on biomarker levels. This
studydesigncannotcontrolforotherday-
to-day factors that could inﬂuence base-
line levels of inﬂammatory markers.
However, the effects of hypoglycemia
could be evaluated, as each participant
acted as their own control. This produces
less variability than a comparison of re-
sults among individuals, as more inter-
individual variation in inﬂammatory
marker levels is present than intra-
individual variation. In addition, it was
possible to analyze each study separately,
byexaminingchangesinparametersfrom
baseline on that particular day, enabling
the detection of signiﬁcant effects exerted
byhypoglycemiacomparedwitheuglyce-
mia. Baseline levels of all markers (except
IL-6) were higher in the diabetic group
(signiﬁcant for P-selectin and CD40 ex-
pression). This could affect the magni-
tude of response induced by the
experimental procedures. However, an
analysis of the percentage change from
baseline was consistent with the trends
identiﬁed in the absolute results (shown
as in the online appendix available at
http://care.diabetesjournals.org/cgi/
content/full/dc10-0013/DC1).
As anticipated, epinephrine secre-
tion was stimulated by hypoglycemia. It
islikelythathormonalchangesunderlie
the activation and upregulation of the
vascular biomarkers. Catecholamines
promote platelet activation (22), while
adrenoceptor blockade attenuates these
effects (23,24). The participants with
type 1 diabetes exhibited attenuated
plasma epinephrine responses to hypo-
glycemia compared with the nondia-
betic subjects, who were naïve to such a
hypoglycemic stimulus, this being con-
sistent with the recognized decline in
the magnitude of counterregulatory
hormonal responses with increasing
duration of type 1 diabetes (25). This
attenuated epinephrine response may
explain the lower responses of vascular
biomarkers to hypoglycemia.
In summary, the effects of hypogly-
cemia on several vascular biomarkers
that are implicated in the pathogenesis
of vascular disease, would support the
premise that acute hypoglycemia may
be detrimental to an already diseased
vasculature (2). Euglycemia may have a
protective, anti-inﬂammatory effect. In
the present study, the participants had
no overt vascular disease and were un-
likely to develop any demonstrable ef-
fects from a short period of exposure to
hypoglycemia. However, in people with
diabetesoflongduration,whoarelikely
to have underlying vascular disease,
these responses may not be benign. The
release of potent vasoactive substances
could potentially aggravate chronic vas-
culopathy,andcontributetotheprecip-
itation of acute macrovascular events.
This may aggravate established diabetic
micro- and macrovascular disease in
those who are exposed to recurrent
hypoglycemia.
Acknowledgments— The cost of assays was
supportedbyresearchgrantsfromtheScottish
Society of Physicians and the Edinburgh
branch of Diabetes UK.
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Hanssen KF, Dahl-Jørgensen K, Lauritzen
T, Feldt-Rasmussen B, Brinchmann-Han-
sen O, Deckert T. Diabetic control and
microvascular complications: the near-
normoglycaemic experience. Diabetolo-
gia 1986;29:677–684
2. Frier BM, Hilsted J. Does hypoglycaemia
aggravate the complications of diabetes?
Lancet 1985;2:1175–1177
3. WrightRJ,FrierBM.Vasculardiseaseand
diabetes:ishypoglycaemiaanaggravating
factor? Diabetes Metab Res Rev 2008;24:
353–363
4. Action to Control Cardiovascular Risk in
Diabetes Study Group, Gerstein HC,
Miller ME, Byington RP, Goff DC Jr, Big-
ger JT, Buse JB, Cushman WC, Genuth S,
Ismail-Beigi F, Grimm RH Jr, Probstﬁeld
JL, Simons-Morton DG, Friedewald WT
Effects of intensive glucose lowering in
type 2 diabetes. N Engl J Med 2008;358:
2545–2559
5. Duckworth W, Abraira C, Moritz T, Reda
D, Emanuele N, Reaven PD, Zieve FJ,
Marks J, Davis SN, Hayward R, Warren
SR, Goldman S, McCarren M, Vitek ME,
Henderson WG, Huang GD, for the
VADT Investigators. Glucose control and
vascular complications in veterans with
type 2 diabetes. N Engl J Med 2009;360:
129–139
6. FrierBM,CorrallRJ,DavidsonNM,Web-
ber RG, Dewar A, French EB. Peripheral
blood cell changes in response to acute
hypoglycaemia in man. Eur J Clin Inv
1983;13:33–39
7. Fisher BM, Quin JD, Rumley A, Lennie
SE, Small M, MacCuish AC, Lowe GD.
Effects of acute insulin-induced hypogly-
caemia on haemostasis, ﬁbrinolysis and
haemorheology in insulin-dependent di-
abetic patients and control subjects. Clin
Sci 1991;80:525–531
8. Trovati M, Anfossi G, Cavalot F, Vitali S,
Massucco P, Mularoni E, Schinco P, Tam-
poni G, Emanuelli G. Studies on mecha-
nisms involved in hypoglycemia-induced
platelet activation. Diabetes 1986;35:
818–825
9. Galloway PJ, Thomson GA, Fisher BM,
Semple CG. Insulin-induced hypoglyce-
mia induces a rise in C-reactive protein
(Letter). Diabetes Care 2000;23:861
10. DotsonS,FreemanR,FailingHJ,AdlerGK.
Hypoglycemia increases serum interleu-
kin-6levelsinhealthymenandwomen.Di-
abetes Care 2008;31:1222–1223
11. Wright RJ, Macleod KM, Perros P,
Johnston N, Webb DJ, Frier BM. Plasma
endothelin response to acute hypoglycae-
mia in adults with type 1 diabetes. Diabet
Med 2007;24:1039–1042
12. Libby P, Ridker PM, Maseri A. Inﬂamma-
tion and atherosclerosis. Circulation
2002;105:1135–1143
13. De Fronzo R, Tobin JD, Andres R. Glu-
coseclamptechnique:amethodforquan-
tifying insulin secretion and resistance.
Am J Physiol 1979;273:E214–E223
14. Abumrad NN, Rabin D, Diamond MP,
Lacy WW. Use of a heated superﬁcial
hand vein as an alternative site for the
measurement of amino acid concentra-
tions and for the study of glucose and ala-
nine kinetics in man. Metabolism 1981;
30:936–940
15. Gold AE, MacLeod KM, Frier BM. Fre-
quency of severe hypoglycemia in pa-
tients with type 1 diabetes with impaired
awareness of hypoglycemia. Diabetes
Care 1994;17:697–703
16. Thompson CJ, Baylis PH. Endocrine
changes during insulin-induced hypogly-
caemia. In Hypoglycaemia and Diabetes:
ClinicalandPhysiologicalAspects.FrierBM,
Fisher BM, Eds. Edward Arnold, London,
U.K., 1993, p.116–131
17. Rydzewski A, Urano T, Nagai N, Takada
Y, Katoh-Oishi Y, Taminato T, Yoshimi T,
Takada A. Diurnal variation in serum
remnant-like lipoproteins, platelet aggre-
gation and ﬁbrinolysis in healthy volun-
teers. Haemostasis 1997;27:305–314
18. Dandona P, Chauduri A, Ghanim H, Mo-
hanty P. Insulin as an anti-inﬂammatory
andantiatherogenicmodulator.JAmColl
Cardiol 2009;53 (Suppl. 5):S14–S20
19. Scho ¨nbeck U, Libby P. CD40 signaling
and plaque instability. Circ Res 2001;89:
1092–1103
Hypoglycemia and vascular disease
1596 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.org20. MachF,Scho ¨nbeckU,LibbyP.CD40sig-
naling in vascular cells: a key role in
atherosclerosis? Atherosclerosis 1998;
137(Suppl.):S89–S95
21. RazaviNematollahiL,KitabchiAE,Kitab-
chi AE, Stentz FB, Wan JY, Larijani BA,
Tehrani MM, Gozashti MH, Omidfar K,
Taheri E. Proinﬂammatory cytokines in
response to insulin-induced hypoglyce-
micstressinhealthysubjects.Metabolism
2009;58:443–448
22. Steel CM, French EB, Aitchison WR.
Studiesonadrenaline-inducedleucocyto-
sisinnormalman.I.Theroleofthespleen
and of the thoracic duct. Br J Haematol
1971;21:413–421
23. Fisher BM, Hepburn DA, Smith JG, Frier
BM. The effect of alpha-adrenergic block-
adeonresponsesofperipheralbloodcells
to acute insulin-induced hypoglycaemia
in humans. Eur J Clin Invest 1990;
20:51–55
24. Takeda H, Kishikawa H, Shinohara
M, Miyata T, Suzaki K, Fukushima H,
Ichinose K, Shichiri M. Effect of alpha
2-adrenoceptor antagonist on platelet
activation during insulin-induced hypo-
glycaemia in type 2 (noninsulin-depen-
dent) diabetes mellitus. Diabetologia
1988;31:657–663
25. Kerr D, Richardson T. Counterregula-
torydeﬁcienciesindiabetes.InHypogly-
caemia in Clinical Diabetes. 2nd edition.
FrierBM,FisherM,Eds.JohnWileyand
Sons, Chichester, U.K., 2007, p. 121–
140
Wright and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1597